

The Manager
Company Announcements Office
ASX Limited

LBT COMPLETES AUSTRALIAN CLINICAL TRIALS OF APAS® TECHNOLOGY

Adelaide, 26 November 2014: Medical technology company LBT Innovations Limited (ASX: LBT) has completed two comprehensive clinical trials of its pioneering culture-plate analysis technology, the Automated Plate Assessment System (APAS®), at the laboratories of Healthscope Pathology in Melbourne and Adelaide.

The trials successfully tested the efficacy of the APAS technology in detecting and reporting the presence of disease-causing pathogens in urine samples from a total of 4,300 patients. A full report of the findings is being submitted to the United States Food and Drug Administration (FDA), prior to the commencement of a US trial early in 2015.

LBT is maintaining close consultation with the FDA to confirm that its trial protocols continue to meet the strict guidelines required for a 510(k) *de novo* submission, which will be required before APAS can be distributed commercially in the US market.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company has two breakthrough products in microbiology automation: PREVI® Isola, which provides automation of culture plate streaking, and APAS®, a breakthrough in automated culture plate imaging, interpretation and reporting. LBT also has a third product in development, Woundvue™, a proposed automation solution to assist in the management of chronic wounds.

LBT has an exclusive global licence agreement with French diagnostics company bioMérieux to manufacture and market PREVI® Isola. LBT receives ongoing royalty payments for PREVI Isola, which has been installed in clinical laboratories around the world. LBT's APAS® technology (Automated Plate Assessment System) is nearing market. Based on LBT's innovative intelligent image interpretative platform, APAS specifically addresses the automated imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a Joint Venture with Hettich AG Switzerland to drive the commercial development and global distribution of APAS instrumentation and software products.

For more information, see www.lbtinnovations.com

CONTACTS

LBT Innovations	Media Relations
Lusia Guthrie CEO Tel: +61 (0)8 8227 1555 E: info@lbtinnovations.com	Rudi Michelson Monsoon Communications Tel: +61 (0)3 9620 3333 E: rudim@monsoon.com.au